FABIO GRUNSPUN PITTA

(Fonte: Lattes)
Índice h a partir de 2011
5
Lattes
ResearcherID
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/11 - Laboratório de Cirurgia Cardiovascular e Fisiopatologia da Circulação, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Autor: PITTA, Fabio G. ×

Resultados de Busca

Agora exibindo 1 - 9 de 9
  • conferenceObject
    Two-year Follow-up Of Patients With Chronic Ischemic Heart Disease In A Specialized Center In Brazil
    (2021) PINESI, Henrique Trombini; MOREIRA, Eduardo M.; BOLTA, Paula M.; MARTINS, Eduardo B.; PITTA, Fabio G.; REZENDE, Paulo C.; LIMA, Eduardo G.; HUEB, Whady; GARZILLO, Cibele L.; SERRANO, Carlos V.
  • conferenceObject
    Gender-related Differences in the Management of Chronic Coronary Syndrome: Registry Data of a Tertiary Center in Brazil
    (2020) SERRANO, Carlos V.; MOREIRA, Eduardo M.; GARZILLO, Cibele L.; MONTENEGRO, Luiz M.; TABUSE, Cindy L.; KORMANN-MOREIRA, Mylena C.; SEGRE, Alexandre W.; BOLTA, Paula M.; FAVARATO, Desiderio; PITTA, Fabio G.; LIMA, Eduardo G.; REZENDE, Paulo H.; HUEB, Whady A.
  • conferenceObject
    Neither Moderate Consumption of Sugarcane Liquor (""Cachaca"") Nor of Red Wine Affect Cardiovascular Risk Biomarkers in Healthy Individuals
    (2020) CELLIA, Pedro H.; LIMA, Eduardo G.; MOREIRA, Eduardo; BARBOSA, Livia B.; PITTA, Fabio G.; RACHED, Fabiana H.; STRUNZ, Celia M.; FAVARATO, Desiderio; GARZILLO, Cibele L.; SERRANO, Carlos V.
  • article 8 Citação(ões) na Scopus
    Effectiveness and safety of iodopovidone in an experimental pleurodesis model
    (2013) TEIXEIRA, Lisete R.; VARGAS, Francisco S.; PUKA, Juliana; ACENCIO, Milena M. P.; ANTONANGELO, Leila; TERRA, Ricardo M.; DAMICO, Francisco M.; PITTA, Fabio G.; MARCHI, Evaldo
    OBJECTIVES: Chemical pleurodesis is an important therapeutic tool to control recurrent malignant pleural effusion. Among the various sclerosing agents, iodopovidone is considered effective and safe. However, in a recent study, ocular changes were described after iodopovidone was used in recurrent pneumothorax. The aim of the study was to evaluate the efficacy and morbidity of iodopovidone pleurodesis in an experimental model. METHODS: New Zealand rabbits were submitted to intrapleural injection of iodopovidone at concentrations of 2%, 4% and 10%. Biochemical (lactic dehydrogenase, proteins, triiodothyronine, free thyroxine, urea and creatinine) and immunological (Interleukin-8 [IL-8], VEGF and TGF beta) parameters were measured in the pleural fluid and blood. After 1, 3, 7, 14 and 28 days, groups of animals were euthanized, and macro-(pleura) and microscopic (pleura and retina) analyses were performed. RESULTS: An early pleural inflammatory response with low systemic repercussion was observed without corresponding changes in thyroid or renal function. The higher concentrations (4% and 10%) correlated with greater initial exudation, and maximum pleural thickening was observed after 28 days. No changes were observed in the retinal pigment epithelium of the rabbits. CONCLUSION: Iodopovidone is considered to be an effective and safe sclerosing agent in this animal model. However, its efficacy, tolerance and safety in humans should be further evaluated.
  • article 30 Citação(ões) na Scopus
    Association between Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios and Coronary Artery Calcification Score among Asymptomatic Patients: Data from a Cross-Sectional Study
    (2019) SERRANO JR., Carlos V.; MATTOS, Fernando R. de; PITTA, Fabio G.; NOMURA, Cesar H.; LEMOS, James de; RAMIRES, Jose Antonio F.; KALIL-FILHO, Roberto
    Introduction. Atherosclerosis is a low-grade inflammatory disease. Among markers of inflammation, importance has been given to the neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR). The objective of this study was to examine the association between these hematological indices of inflammation and coronary atherosclerotic calcification in clinically asymptomatic patients. Methods. This study had clinical and laboratorial data collected from consecutive asymptomatic patients that underwent computed tomography coronary artery calcium (CAC) scoring. Risk factors, NLR, and PLR were evaluated at different categories of CAC scoring. Statistical tests included chi-square, linear regression, and logistic regression. Patients (N=247; age 60.4 +/- 8.0 years and 60.7% men) were allocated into four categories according to the CAC score. Results. Respective age, sex (male), NLR, and PLR distribution within groups were as follows: CAC=0 (n=98; 52.5 +/- 13.6 years, 55%, 2.0 +/- 1.0, and 121.5 +/- 41.5), CAC 1-100 (N=64; 61.3 +/- 11.0 years, 60%, 2.2 +/- 1.2, and 125.6 +/- 45.6), CAC 101-400 (N=37; 64.2 +/- 11.6 years, 67%,2.6 +/- 1.3, and 125.4 +/- 55.9), and CAC>400 (N=48; 69.3 +/- 11.1 years, 66%, 3.3 +/- 2.0, and 430.1 +/- 1787.4). The association between risk factors and CAC score was assessed. Hypertension status and smoking status were similar within groups, while the presence of diabetes (P=0.02) and older age (P <= 0.001) was more prevalent in the CAC>400 group. LDL cholesterol was greater in the higher CAC score groups (P=0.002). Multivariate logistic regression of the quartile analysis showed that age and NLR were independently associated with CAC>100 (OR (CI), P value): 2.06 (1.55-2.73, P=0.00001) and 1.82 (1.33-2.49, P=0.0002), respectively. Conclusion. Within asymptomatic patients, NLR provides additional risk stratification, as an independent association between NLR extent and CAD extent was identified. Moreover, PLR was not an inflammation marker for CAD severity.
  • conferenceObject
    Diabetes and Chronic Kidney Disease: Prevalence, Associated Factors and Influence on Optimal Medical Therapy in Patients with Coronary Artery Disease
    (2021) MOREIRA, Eduardo M.; PINESI, Henrique Trombini; BOLTA, Paula; MARTINS, Eduardo; RACHED, Fabiana H.; PITTA, Fabio G.; FAVARATO, Desiderio; LIMA, Eduardo G.; GARZILLO, Cibele L.; SEGRE, Carlos A.; SERRANO, Carlos V.
  • article 3 Citação(ões) na Scopus
    P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with acute coronary syndromes undergoing coronary stenting: rationale and design of the NEOMINDSET Trial
    (2023) GUIMARES, Patricia O.; FRANKEN, Marcelo; TAVARES, Caio A. M.; SILVEIRA, Fabio S.; ANTUNES, Murillo O.; BERGO, Ricardo R.; JOAQUIM, Rodrigo M.; HIRAI, Jessica C. S.; ANDRADE, Pedro B.; PITTA, Fabio G.; MARIANI JR., Jose; NASCIMENTO, Bruno R.; SILVEIRA, Marcos S.; COSTA, Tiberio A. O.; DALL'ORTO, Frederico T. C.; SERPA, Renato G.; SAMPAIO, Fernanda B. A.; OHE, Louis N.; MANGIONE, Fernanda M.; FURTADO, Remo H. M.; SARMENTO-LEITE, Rogerio; MONFARDINI, Frederico; ASSIS, Silvia R. L.; NICOLAU, Jose C.; SPOSITO, Andrei C.; LOPES, Renato D.; ONUMA, Yoshinobu; VALGIMIGLI, Marco; ANGIOLILLO, Dominick J.; SERRUYS, Patrick W.; BERWANGER, Otavio; BACAL, Fernando; LEMOS, Pedro A.
    Dual antiplatelet therapy (DAPT) is currently the standard of care after percutaneous coronary interven-tion (PCI). Recent studies suggest that reducing DAPT to 1-3 months followed by an aspirin-free single antiplatelet therapy (SAPT) strategy with a potent P2Y12 inhibitor is safe and associated with less bleeding. However, to date, no randomised trial has tested the impact of initiating SAPT immediately after PCI, par-ticularly in patients with acute coronary syndromes (ACS). NEOMINDSET is a multicentre, randomised, open-label trial with a blinded outcome assessment designed to compare SAPT versus DAPT in 3,400 ACS patients undergoing PCI with the latest-generation drug-eluting stents (DES). After successful PCI and up to 4 days following hospital admission, patients are randomised to receive SAPT with a potent P2Y12 inhibitor (ticagrelor or prasugrel) or DAPT (aspirin plus a potent P2Y12 inhibitor) for 12 months. Aspirin is discontinued immediately after randomisation in the SAPT group. The choice between ticagrelor and prasugrel is at the investigator's discretion. The primary hypothesis is that SAPT will be non-inferior to DAPT with respect to the composite endpoint of all-cause mortality, stroke, myocardial infarction or urgent target vessel revascularisation, but superior to DAPT on rates of bleeding defined by Bleeding Academic Research Consortium 2, 3 or 5 criteria. NEOMINDSET is the first study that is specifically designed to test SAPT versus DAPT immediately following PCI with DES in ACS patients. This trial will provide impor-tant insights on the efficacy and safety of withdrawing aspirin in the early phase of ACS. (ClinicalTrials. gov: NCT04360720)
  • conferenceObject
    The Challenge of Treating a Previously Surgical Revascularized Patient With Acute ST-Elevation Myocardial Infarction (STEMI) and Coronary- Subclavian Steal Syndrome
    (2021) PINESI, Henrique Trombini; MARINS, Pedro H.; BALZAN, Hadrien F.; HABRUM, Fabio Cetinic; MATUCK, Bruna R.; MEDEIROS, Marina A. de; PITTA, Fabio G.; LIMA, Eduardo G.; GARZILLO, Cibele L.; SERRANO, Carlos V.
  • article 30 Citação(ões) na Scopus
    Regression of Atherosclerotic Plaques of Cholesterol-Fed Rabbits by Combined Chemotherapy With Paclitaxel and Methotrexate Carried in Lipid Core Nanoparticles
    (2018) GOMES, Fernando L. T.; MARANHAO, Raul C.; TAVARES, Elaine R.; CARVALHO, Priscila O.; HIGUCHI, Maria L.; MATTOS, Fernando R.; PITTA, Fabio G.; HATAB, Sergio A.; KALIL-FILHO, Roberto; SERRANO JR., Carlos V.
    In previous studies, it was demonstrated that lipid core nanoparticles (LDE) resemble the low-density lipoprotein structure and carrying the antiproliferative agent paclitaxel (PTX) strongly reduced atherosclerosis lesions induced in rabbits by cholesterol feeding. Currently, the aim was to verify whether combining LDE-PTX treatment with methotrexate (MTX) associated with LDE (LDE-MTX) could accelerate the atherosclerosis regression attained with single LDE-PTX treatment, after withdrawing the cholesterol feeding. Thirty-eight rabbits were fed 1% cholesterol chow for 8 weeks. Six of these rabbits were then euthanized for analyses of the aorta (controls). In the remaining rabbits, cholesterol feeding was withdrawn, and those 32 animals were allocated to 3 groups submitted to different 8-week intravenous treatments, all once/week: LDE-PTX (n = 10; 4 mg/kg), LDE-PTX + LDE-MTX (n = 11; 4 mg/kg), and LDE-alone (n = 11). Rabbits were then euthanized and aortas were excised for morphometric, immunohistochemical, and gene expression analyses. After cholesterol feeding withdrawal, in comparison with LDE-alone group, both LDE-PTX and LDE-PTX + LDE-MTX treatments had the ability to increase the regression of plaque areas: -49% in LDE-PTX and -59% for LDE-PTX + LDE-MTX. However, only LDE-PTX + LDE-MTX treatment elicited reduction in the intima area, estimated in -57%. Macrophage presence in aortic lesions was reduced 48% by LDE-PTX and 43% by LDE-PTX + LDE-MTX treatment. Matrix metalloproteinase 9 was reduced by either LDE-PTX (74%) or LDE-PTX + LDE-MTX (78%). Tumor necrosis factor gene expression was reduced 65% by LDE-PTX and 79% by LDE-PTX + LDE-MTX. In conclusion, treatment with LDE-PTX indeed accelerated plaque reduction after cholesterol feeding; LDE-PTX + LDE-MTX further increased this effect, without any observed toxicity. These results pave the way for the use of combined chemotherapy to achieve stronger effects on aggravated, highly inflamed atherosclerotic lesions.